009420 — Hanall Biopharma Share News
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩2tn
- KR₩155bn
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Brief: Hanall Biopharma Q4 Operating Loss 2 Billion Won
Brief: Hanall Biopharma Q3 Operating Profit 349 Million Won, Down 19% From Year Earlier
Brief: Hanall Biopharma Q2 Operating Profit 1 Billion Won, Swings To Profit From Year Earlier
Brief: Hanall Biopharma Q1 Operating Loss 394 Million Won
Brief: Hanall Biopharma To Acquire 3.2 Billion Won Worth Of Own Shares
H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating
Brief: Hanall Biopharma Q4 Operating Profit 2.7 Billion Won, Swings To Profit From Year Earlier
Brief: HanAll Biopharma, Daewoong Pharma And NurrOn Pharma Complete First Human Study for Parkinson's Therapy
Halozyme Therapeutics rises after raising FY forecast, upbeat Q3 results
Brief: Hanall Biopharma Reports Q3 2024 Financial Results And Provides Business Update
Brief: Hanall Biopharma Co Ltd Q3 Operating Profit 430 Million Won, Up 372% From Year Earlier
Biohaven down after $250 mln stock offering prices
Australia's Syntara falls on discounted placement
Brief: Hanall Biopharma Q2 Operating Loss 3 Billion Won
Rezolute tumbles on pricing stock offering